The Protective Effects Trimetazidine on Indomethacin Induced Gastric Ulcer in Rat Model

Abstract

Introduction: Gastric ulcer (GU) is the most common gastrointestinal tract disorder, representing about 20% of peptic ulcer due to an imbalance between gastric defense mechanisms and aggressive factors, mainly Helicobacter pylori and non-steroidal anti-inflammatory drugs (NSAIDs). The study aims to evaluate trimetazidine’s protective effect on histopathology, GU severity, inflammatory and oxidative stress markers (TNF-alpha, MPO and MDA) in rate model of indomethacin induced GU. Method: Total 30 healthy male albino rats were divided into fiive groups each of ten (N=10). Group A: Given indomethacin vehicles (normal saline 0.9% and tween 80) orally via gavage tube and serve as control positive group. Group B: Induced ulcer by Indomethacin 60 mg/kg orally via oral gavage serve as control negative. Group C: Pretreated with trimetazidine 50 mg/ kg orally by gavage tube 1-hour before administering indomethacin 60 mg/kg. At the end of study histological examination, anti-inflammatory and antioxidant markers were evaluated. Results: TMZ 50 mg/kg pretreated groups show a significant (p < 0.01) reduction in GU severity score and histopathology damage score in comparison with the indomethacin ulcerated group. Moreover, pretreated groups TMZ 50 mg/kg showed a significant reduction in inflammatory markers (TNF-alpha and MPO) and oxidative stress marker (MDA) in comparison with the induction group, similar to the results of the reference drug. Conclusion: TMZ dihydrochloride has similar efficacy as standard omeprazole drug by a decrease in oxidative stress status manifested by a reduction in lipid peroxidation indicator marker and a reduction in pro-inflammatory cytokine level and leukocyte recruitment indicator marker and finally, macroscopic and microscopic evaluation show a reduction GU severity.